UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 10, 2017
STEREOTAXIS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 001-36159 | 94-3120386 | |
| (Commission File Number) |
(IRS Employer Identification No.) | |
| 4320 Forest Park Avenue, Suite 100, St. Louis, Missouri | 63108 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
(314) 678-6100
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition |
On August 10, 2017, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the second quarter of fiscal year 2017. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.
Forward-Looking Statements and Additional Information
Statements are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties and other important factors that could cause events or the Company’s actual performance or achievements to be materially different than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
| 99.1 | Stereotaxis, Inc. Earnings Press Release dated August 10, 2017. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STEREOTAXIS, INC. | ||||||
| Date: August 10, 2017 | By: | /s/ Karen Witte Duros | ||||
| Name: | Karen Witte Duros | |||||
| Title: | Sr. Vice President, General Counsel and Secretary | |||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Stereotaxis, Inc. Earnings Press Release dated August 10, 2017. | |
Exhibit 99.1
Stereotaxis Reports Second Quarter 2017 Financial Results
| • | Stable recurring revenue and 2% year-over-year growth in global procedures |
| • | Reduced operating expenses and operating loss |
| • | Launch of e-Contact™ module in EU and progress in development of strategic innovation plans |
| • | Reaffirming 2017 expectations |
| • | Conference call today at 10:00 a.m. Eastern Time |
ST. LOUIS, MO, August 10, 2017 — Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2017.
David Fischel, Chairman and Acting CEO, commented, “I am pleased with our progress in the quarter from a financial, operational and strategic perspective. Our focus remains on supporting electrophysiologists build successful robotic ablation practices and identifying and initiating the strategic innovation paths that improve patient care, physician choice and our technology availability. The combination of these should enable a future where robotic ablation is standard of care across a broad spectrum of cardiac arrhythmias.”
“During the quarter, we launched the e-Contact™ module in Europe, an important capability on the path to robust automation software. Increased customer engagement led to annual growth in global procedure volumes. Improved expense management led to a meaningful reduction in operating loss. We are working on establishing additional capabilities, relationships and innovation programs that will be announced when appropriate.”
Second Quarter and First Half 2017 Financial Results
Revenue for the second quarter of 2017 totaled $8.5 million, up from $7.9 million in the prior year second quarter and up sequentially from $7.0 million in the 2017 first quarter. Recurring revenue was $6.6 million in the second quarter, down from $6.9 million in the prior year quarter and $6.8 million in the first quarter. Recurring revenue for the first half of 2017 of $13.4 million was essentially flat with the first half of 2016. Recurring revenue fluctuates with the timing of disposable shipments and field service projects, but benefited from 2% year-over-year growth in global procedures. System revenue in the second quarter was $1.8 million, up from $0.9 million in the prior year quarter and $0.2 million in the first quarter. System revenue reflected the sale of a Niobe® system to an international distributor in the second quarter as well as the sale of Odyssey® systems. System revenue of $2.0 million for the first half of 2017 was down from $3.0 million in the first half of 2016, primarily reflecting the expiration of an Odyssey distribution agreement and the timing of Niobe system installations in 2016. Ending capital backlog for the 2017 second quarter was $3.2 million.
Gross margin in the quarter was $6.3 million, or 74% of revenue, versus $6.8 million, or 86% of revenue, in the second quarter of 2016 and $5.7 million, or 82% of revenue, in the first quarter of 2017. The reduction in gross margin percentage does not reflect any fundamental changes in product pricing or costs but is primarily the result of higher system sales in the second quarter of 2017 as well as the launch and installation of e-Contact technology at European hospitals. Gross margin of 78% for the first half of 2017 was essentially equivalent to the gross margin recorded for the full year 2016.
Operating expenses in the second quarter were $6.7 million, down from $8.4 million in the prior year quarter and $7.6 million in the first quarter. The reduction in operating expenses reflects lower executive compensation and more efficient management of expenses across the organization, but does not represent any material changes in the organization’s personnel, infrastructure or capabilities. Operating loss in the second quarter was $(0.4) million, a significant reduction compared to $(1.6) million in the prior year second quarter and $(1.9) million in the first quarter. Net loss for the second quarter was $(0.2) million, compared to a net loss of $(2.3) million in the second quarter of 2016. Excluding mark-to-market warrant revaluation, the Company would have reported a net loss of $(0.5) million for the quarter. Cash utilization for the second quarter was $(0.7) million. Cash utilization in the quarter does not reflect the receipt of cash from the sale of the Niobe system, with which the Company would have had recorded positive free cash flow.
Cash Balance and Liquidity
At June 30, 2017, Stereotaxis had cash and cash equivalents of $5.0 million, no debt, and $3.9 million in unused borrowing capacity on its revolving credit facility, for total liquidity of $8.9 million.
Full Year 2017 Expectations
The Company is reaffirming each of the expectations for 2017 that were initially provided in May:
| • | Full year 2017 expected revenue to exceed $30 million |
| • | Approximately cash flow neutral for the last three quarters of 2017 |
| • | Development and initiation of long term product innovation plan |
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain
additional financing, in either case on acceptable terms, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
Stereotaxis Contacts:
David Fischel
Chairman and Acting Chief Executive Officer
Martin C. Stammer
Chief Financial Officer
investors@stereotaxis.com
STEREOTAXIS, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue: |
||||||||||||||||
| Systems |
$ | 1,828,439 | $ | 935,978 | $ | 2,047,334 | $ | 3,010,997 | ||||||||
| Disposables, service and accessories |
6,638,587 | 6,938,645 | 13,397,364 | 13,511,632 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenue |
8,467,026 | 7,874,623 | 15,444,698 | 16,522,629 | ||||||||||||
| Cost of revenue: |
||||||||||||||||
| Systems |
920,517 | 395,898 | 1,140,961 | 1,478,996 | ||||||||||||
| Disposables, service and accessories |
1,281,729 | 699,173 | 2,317,911 | 1,796,888 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total cost of revenue |
2,202,246 | 1,095,071 | 3,458,872 | 3,275,884 | ||||||||||||
| Gross margin |
6,264,780 | 6,779,552 | 11,985,826 | 13,246,745 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Research and development |
1,281,264 | 1,421,380 | 2,439,697 | 2,894,465 | ||||||||||||
| Sales and marketing |
3,472,619 | 4,211,706 | 7,098,219 | 8,105,819 | ||||||||||||
| General and administrative |
1,945,676 | 2,786,046 | 4,785,546 | 5,372,838 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
6,699,559 | 8,419,132 | 14,323,462 | 16,373,122 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating loss |
(434,779 | ) | (1,639,580 | ) | (2,337,636 | ) | (3,126,377 | ) | ||||||||
| Other income |
300,255 | 135,370 | 3,429,563 | 166,664 | ||||||||||||
| Interest income |
1 | 140 | 9 | 362 | ||||||||||||
| Interest expense |
(42,776 | ) | (829,046 | ) | (92,267 | ) | (1,648,066 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
$ | (177,299 | ) | $ | (2,333,116 | ) | $ | 999,669 | $ | (4,607,417 | ) | |||||
| Cumulative dividend on convertible preferred stock |
(369,661 | ) | — | (732,849 | ) | — | ||||||||||
| Net income attributable to convertible preferred stock |
— | — | (167,539 | ) | — | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Earnings (net loss) attributable to common stockholders |
$ | (546,960 | ) | $ | (2,333,116 | ) | $ | 99,281 | $ | (4,607,417 | ) | |||||
|
|
|
|
|
|
|
|
|
|||||||||
| Earnings (net loss) per common share: |
||||||||||||||||
| Basic |
$ | (0.02 | ) | $ | (0.11 | ) | $ | 0.00 | $ | (0.21 | ) | |||||
| Diluted |
$ | (0.02 | ) | $ | (0.11 | ) | $ | 0.00 | $ | (0.21 | ) | |||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average shares used in computing earnings (net loss) per common share: |
||||||||||||||||
| Basic |
22,581,330 | 21,793,583 | 22,450,392 | 21,702,597 | ||||||||||||
| Diluted |
22,581,330 | 21,793,583 | 22,458,479 | 21,702,597 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
STEREOTAXIS, INC.
BALANCE SHEETS
| June 30, 2017 |
December 31, 2016 |
|||||||
| (Unaudited) | ||||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 5,035,463 | $ | 8,501,392 | ||||
| Accounts receivable, net of allowance of $603,588 and $379,817 in 2017 and 2016, respectively |
4,876,716 | 4,665,959 | ||||||
| Inventories |
4,984,115 | 5,381,103 | ||||||
| Prepaid expenses and other current assets |
617,412 | 855,295 | ||||||
|
|
|
|
|
|||||
| Total current assets |
15,513,706 | 19,403,749 | ||||||
| Property and equipment, net |
792,367 | 1,086,244 | ||||||
| Intangible assets, net |
336,908 | 436,569 | ||||||
| Other assets |
41,047 | 39,241 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 16,684,028 | $ | 20,965,803 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ deficit |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 1,737,247 | $ | 2,623,010 | ||||
| Accrued liabilities |
3,887,511 | 4,491,164 | ||||||
| Deferred revenue |
8,101,667 | 8,751,336 | ||||||
| Warrants |
16,357,444 | 19,787,007 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
30,083,869 | 35,652,517 | ||||||
| Long-term deferred revenue |
377,076 | 522,329 | ||||||
| Other liabilities |
321,316 | 320,409 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
30,782,261 | 36,495,255 | ||||||
| Convertible preferred stock: |
||||||||
| Convertible preferred stock, par value $0.001; 10,000,000 shares authorized, 23,900 shares outstanding at 2017 and 2016 |
5,960,475 | 5,960,475 | ||||||
| Stockholders’ deficit: |
||||||||
| Common stock, par value $0.001; 300,000,000 shares authorized, 22,612,043 and 22,063,582 shares issued at 2017 and 2016, respectively |
22,612 | 22,064 | ||||||
| Additional paid-in capital |
450,370,408 | 449,939,406 | ||||||
| Treasury stock, 4,015 shares at 2017 and 2016 |
(205,999 | ) | (205,999 | ) | ||||
| Accumulated deficit |
(470,245,729 | ) | (471,245,398 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ deficit |
(20,058,708 | ) | (21,489,927 | ) | ||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ deficit |
$ | 16,684,028 | $ | 20,965,803 | ||||
|
|
|
|
|
|||||